Alejandro Chertkoff
Impact in
-
- Diabetes Treatment and Management
- Diabetes Management and Research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pharmacology top 5%
- Pharmacology and Obesity Treatment
Papers in
-
- Diabetes Treatment and Management 2
- Diabetes Management and Research 1
-
- Health and Lifestyle Studies 1
- Journals
- The Lancet (2 papers)Diabetes Care (1 paper)DOAJ (DOAJ: Directory of Open Access Journals) (1 paper)
In The Last Decade
Alejandro Chertkoff
3 papers receiving 1.9k citations
Alejandro Chertkoff's Hit Papers
Peers
Comparison fields: 5 of 67
- Endocrinology, Diabetes and Metabolism 1.6k
- Pharmacology 307
- Cardiology and Cardiovascular Medicine 206
- Surgery 367
- Physiology 177
Countries citing papers authored by Alejandro Chertkoff
This map shows the geographic impact of Alejandro Chertkoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejandro Chertkoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejandro Chertkoff more than expected).
Fields of papers citing papers by Alejandro Chertkoff
This network shows the impact of papers produced by Alejandro Chertkoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejandro Chertkoff. The network helps show where Alejandro Chertkoff may publish in the future.
Co-authors
The 2 scholars most cited alongside Alejandro Chertkoff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Hit paper breakdown → | 2018 | 1430 |
| 2 | Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Hit paper breakdown → | 2021 | 538 |
| 3 | 2025 | 6 | |
| 4 | 2020 | 0 |
About Alejandro Chertkoff
Alejandro Chertkoff is a scholar working on Endocrinology, Diabetes and Metabolism, General Health Professions, Insect Science, Renewable Energy, Sustainability and the Environment and Obstetrics and Gynecology, having authored 4 papers that have together received 2.0k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (2 papers), Diabetes Management and Research (1 paper) and Health and Lifestyle Studies (1 paper). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.6k citations), Pharmacology (307 citations), Cardiology and Cardiovascular Medicine (206 citations), Surgery (367 citations) and Physiology (177 citations). Alejandro Chertkoff has collaborated with scholars based in Brazil and Argentina. Frequent co-authors include Víctor Commendatore and Gustavo Daniel Frechtel. Their work appears in journals such as The Lancet, Diabetes Care and DOAJ (DOAJ: Directory of Open Access Journals).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.